The 2026 tau imaging news adds a clearer staging option to Alzheimer's workups: memory-clinic patients can compare low-burden blood triage, confirmatory amyloid testing, and newer tau PET for stage and prognosis. Tau means neurofibrillary tangles, twisted tau fibers that spread as thinking declines.
On Aug. 14, 2026, the FDA approved Tauklarify for brain PET in cognitively impaired adults being evaluated for Alzheimer's to spot that tangle pathology, as Lantheus reported in the FDA approval notice. Blood tests cleared around the same time can help sort amyloid risk first, leaving tau PET for selected staging questions.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the new tau PET scan adds
- Where blood tests fit first
- How can patients compare testing options?
- What are the key limits?
What the new tau PET scan adds
Tauklarify uses florquinitau F 18, also called MK-6240, to highlight tau tangles during a brain PET scan. It is meant for adults who already have cognitive impairment and are being evaluated for Alzheimer's. Approval rested on two blinded read studies in more than 500 participants.
Readers agreed strongly, with high negative agreement and lower positive agreement. A same-person comparison found MK-6240 detected tangles earlier than the older tracer Tauvid and better separated Alzheimer-related impairment. That edge matters for staging, because earlier tangle signal can sharpen prognosis and trial matching.
Where blood tests fit first
Blood tests measure Alzheimer-related signals without a scan or spinal tap. On Aug. 24, 2026, the FDA cleared Roche's single-biomarker Elecsys pTau217 blood test to help rule amyloid pathology in or out in symptomatic adults 55 and older, according to Practical Neurology in the test clearance summary. On Aug.
20, 2026, the FDA cleared C2N's PrecivityAD2 for symptomatic adults 40 and older. It combines amyloid Aβ42/40 and p-tau217 ratios by mass spectrometry as an aid to workup, not a standalone diagnosis. The Alzheimer's Association's 2025 guideline limits blood biomarker use to patients with objective impairment seen in specialty memory care, as the Association stated in the guideline release. High-accuracy tests can triage patients, and only the most accurate may replace PET or spinal-fluid testing.
How can patients compare testing options?
Think in layers: screen, confirm, stage. Blood triage comes first for many patients because it is lower burden.
Confirmatory amyloid PET or spinal fluid follows when treatment, trial, or diagnostic certainty requires it. Bring prior records, medication lists, and symptom timelines to that visit. Ask what each result would change: diagnosis, drug choice, trial referral, or watchful follow-up.
- Start with clinical exam plus cognitive testing to document objective impairment.
- Ask whether a high-accuracy blood test can triage amyloid likelihood.
- Reserve amyloid PET or spinal fluid for confirmation when results will change care.
- Reserve newer tau PET for clarifying stage, prognosis, or therapy and trial eligibility where available.
What are the key limits?
Tau PET and blood tests do not diagnose Alzheimer's alone. Clinical evaluation remains required, including history, exam, and cognitive testing. Safety and effectiveness of Tauklarify are not established for non-Alzheimer tauopathies.
A positive tangle scan has different meaning in frontotemporal degeneration, progressive supranuclear palsy, or other tau conditions. Access also varies by center, insurance, and referral rules. Ask your memory clinic whether tau PET is offered locally, what it costs you, and whether a trial site can provide it.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Memory Clinic Patients Can Compare Testing Options
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: How Memory Clinic Patients Can Compare Testing Options
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: How Memory Clinic Patients Can Compare Testing Options
